Array Biopharma melanoma drug succeeds in late-stage study
Dec 16 (Reuters) - Drug developer Array BioPharma Inc said its experimental drug helped patients with a form of melanoma live longer without their cancer progressing, in a late-stage study.
The drug, binimetinib, met the main goal of improving progression-free survival (PFS) compared with chemotherapy in the ongoing trial, the company said.
(Reporting by Natalie Grover in Bengaluru; Editing by Shounak Dasgupta)